MedTrace Logo

A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer

NCT07055568 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-07-09

No results posted yet for this study

Summary

To evaluate the preliminary safety and tolerability of iNKT cell injection after infusion in each group of subjects, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for extended studies.

Conditions

Interventions

DRUG

iNKT

iNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-09-30
Completion
2028-01-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07055568 on ClinicalTrials.gov